Abstracts Archive - Page 552 of 2425 - ACR Meeting Abstracts

Abstract Number: 1746 • ACR Convergence 2021
Baricitinib Decreases Anti-dsDNA and IgG Antibodies in Adults with Systemic Lupus Erythematosus from a Phase 2 Double-Blind, Randomized, Placebo-Controlled Trial
Thomas Dörner¹, Ronald Van Vollenhaven², Andrea Doria³, Bochao Jia⁴, Damiano Fantini⁴, Jorge Ross Terres⁴, Maria Silk⁵, Stephanie de Bono⁴, Peter Fischer⁶ and Daniel Wallace⁷, ¹Charite Universitätsmedizin Berlin and Deutsches Rheumaforschungszentrum (DRFZ), Berlin, Germany, ²University Medical Center, Amsterdam, Netherlands, ³University of Padova, Padova, Italy, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Eli Lilly and Company, Carmel, IN, ⁶Eli Lilly and Company, North Easton, MA, ⁷Cedars-Sinai, Los Angeles, CA
Background/Purpose: Baricitinib (BARI), an oral, selective Janus kinase (JAK)1 and JAK2 inhibitor, improved disease activity in adults with systemic lupus erythematosus (SLE) receiving standard background…
Abstract Number: 1738 • ACR Convergence 2021
Uveitis Status in Patients with Ankylosing Spondylitis or Psoriatic Arthritis Under Secukinumab Treatment – Real World Data from a German Observational Study
Uta Kiltz¹, Jan Brandt-Jrgens², Peter Kästner³, Elke Riechers⁴, Daniel Peterlik⁵, Annika Boas⁶ and Hans-Peter Tony⁷, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²Rheumatologische Schwerpunktpraxis, Berlin, Germany, ³Ambulantes Rheumazentrum Erfurt, Erfurt, Germany, ⁴Department for Rheumatology and Immunology, Hannover Medical University, Hannover, ⁵Novartis Pharma GmbH, Nürnberg, Germany, ⁶Novartis Pharma GmbH, Nuernberg, Germany, ⁷Universitätsklinikum Würzburg, Wuerzburg, Germany
Background/Purpose: Uveitis is a well-known non-musculoskeletal manifestation of spondyloarthropathies. Patients typically suffer from blurred vision, pain, and photophobia and have an increased risk of ocular…
Abstract Number: 1629 • ACR Convergence 2021
Effect of Drug Withdrawal on Interleukin-1 or Interleukin-6 Inhibitor Associated Diffuse Lung Disease
Vivian Saper¹, Sampath Prahalad², Scott Canna³, Rabheh Abdul-Aziz⁴, Marcela Alvarez⁵, Catherine Bingham⁶, Brigitte Bader-Meunier⁷, Imelda Balboni⁸, Roberta Berard⁹, Roxana Bolaria¹⁰, Alexis Boneparth¹¹, Alicia Casey¹², Elaine Cassidy¹³, Joyce C. Chang¹⁴, Michal Cidon¹⁵, Kathleen Collins¹⁶, Aileen M. Dickenson¹⁷, Graciela Espada⁵, Martha Fishman¹², Elaine Flanagan¹⁸, Timothy Hahn¹⁹, Ankur K. Jindal²⁰, Ozgur Kasapcopur²¹, Marisa Klein-Gitelman²², Timothy Klouda¹², Mikhail Kostik²³, Carol Lake²⁴, Mariana Marques²⁵, Michael Ombrello²⁶, Karen Onel²⁷, Omkar Phadke²⁸, Angelo Ravelli²⁹, Adam Reinhardt³⁰, Amanda D. Robinson³¹, Kelly Rouster-Stevens³², Nadine Saad²⁷, Grant Schulert³³, Susan Shenoi³⁴, Cory Stingl¹⁴, Anjali Sura³⁵, Melissa Tesher³⁶, Jessica Tibaldi³⁷, Kathryn Torok³⁸, Cathy Tsin³⁹, Natalia Vasquez-Canizares⁴⁰, D. Sofia Villacis-Nunez⁴¹, Ben Whitehead⁴², Holly Wobma¹², Lawrence Zemel⁴³ and Elizabeth Mellins¹, ¹Stanford University, Stanford, CA, ²Emory + Children's Pediatric Institute, Atlanta, GA, ³Children's Hospital of Philadelphia, Philadelphia, PA, ⁴University at Buffalo, Buffalo, NY, ⁵Hospital de Niños Dr Ricardo Gutierrez, Buenos Aires, Argentina, ⁶Penn State Children's Hospital, Allentown, PA, ⁷Pediatric Immuno-hematology, Necker Hospital, APHP, Paris, France, ⁸Stanford University, Palo Alto, CA, ⁹London Health Sciences Centre, London, ON, Canada, ¹⁰Self, Victoria, BC, Canada, ¹¹Columbia University Medical Center, New York, NY, ¹²Boston Children's Hospital, Boston, MA, ¹³University of Pittsburgh Medical Center Medical Education, Pittsburgh, PA, ¹⁴Children's Hospital of Phildelphia, Philadelphia, PA, ¹⁵Children's Hospital Los Angeles, Los Angeles, CA, ¹⁶LeBonheur Children's Hospital, Memphis, TN, ¹⁷Children's Hospital of Los Angeles, Los Angeles, CA, ¹⁸Emory University and Children's Healthcare of Atlanta, Atlanta, GA, ¹⁹Penn State Childrens Hospital, Hershey, PA, ²⁰Postgraduate Institute of Medical Education and Research, Chandigarh, India, ²¹Istanbul University-Cerrahpasa, Cerrahpasa Medical School, İstanbul, Turkey, ²²Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ²³Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, ²⁴National Institutes of Health, Gaithersburg, MD, ²⁵UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, ²⁶National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²⁷Hospital for Special Surgery, New York, NY, ²⁸EMORY, Atlanta, GA, ²⁹Istituto Giannina Gaslini, Genoa, Italy, ³⁰Boys Town National Research Hospital, Omaha, NE, ³¹UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, ³²Emory University/Children's Healthcare of Atlanta, Atlanta, GA, ³³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³⁴Seattle Children's Hospital, Seattle, WA, ³⁵SUNY Upstate Medical University, Syracuse, NY, ³⁶University of Chicago, Chicago, IL, ³⁷IRCSS Istituto G. Gaslini University of Genoa, Genoa, Italy, ³⁸University of Pittsburgh, Pittsburgh, PA, ³⁹Stanford University, Stanford, ⁴⁰Children's Hospital at Montefiore, Bronx, NY, ⁴¹Children's Healthcare of Atlanta - Emory University, Atlanta, GA, ⁴²Queensland Children's Hospital, Brisbane, Australia, ⁴³CCMC, Hartford, CT
Background/Purpose: Severe delayed hypersensitivity reactions (DHR) are under-recognized in inflammatory conditions, particularly drug reaction with eosinophilia and systemic symptoms (DRESS). Previous work has shown this…
Abstract Number: 1693 • ACR Convergence 2021
Lower Adverse Event and Infection Rates During Tocilizumab Therapy Without Concomitant GC: An Analysis of the ICHIBAN Study
Christof Specker¹, Martin Aringer², Gerd Burmester³, Marvin A. Peters⁴, Michael W. Hofmann⁵, Herbert Kellner⁶, Frank Moosig⁷, Hans-Peter Tony⁸ and Gerhard Fliedner⁹, ¹Evangelisches Krankenhaus, Kliniken Essen-Mitte, Essen, Germany, ²Rheumatology, Medicine III, University Medical Center & Faculty of Medicine, TU Dresden, Dresden, Germany, ³Charité University Medicine Berlin, Berlin, Germany, ⁴Roche Pharma AG, Grenzach-Wyhlen, Germany, ⁵Chugai Pharma Germany GmbH, Frankfurt am Main, Germany, ⁶Hospital Neuwittelsbach, Center for Rheumatology and Gastroenterology, Munich, Germany, Munich, Germany, ⁷Rheumatology Center Schleswig-Holstein Middle, Neumünster, Germany, ⁸Universitätsklinikum Würzburg, Wuerzburg, Germany, ⁹Rheumatology Practice, Osnabrueck, Germany
Background/Purpose: To limit the risk of serious infections, guidelines recommend short term (< 3 months) or low-dose (≤10 mg/day) adjunct glucocorticoids (GCs) to control rheumatoid…
Abstract Number: 1753 • ACR Convergence 2021
Hydroxychloroquine Blood Levels Are Associated with Reduced SLE Disease Activity and Improvements in Cardiovascular Risk Factors
Laurence Magder¹, Michelle Petri² and Daniel Goldman², ¹University of Maryland, Baltimore, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: In SLE, treatment with hydroxychloroquine (HCQ) has been shown to be associated with reduced SLE flares and reduced risk of damage in several different…
Abstract Number: 1725 • ACR Convergence 2021
Higher Prevalence of Aspirin Use with a Specific Educational Tool in SLE Pregnancies: Preliminary Results
Joo Young (Esther) Lee¹, Arielle Mendel², Isabelle Malhamé², Sasha Bernatsky¹ and Evelyne Vinet³, ¹McGill University, Montréal, QC, Canada, ²McGill University Health Centre, Montréal, QC, Canada, ³McGill University Health Centre, Mont Royal, QC, Canada
Background/Purpose: Pregnant women with SLE are at substantial risk of preeclampsia. Best international practice guidelines recommend aspirin (ASA) in this population, as it reduces preeclampsia…
Abstract Number: 1743 • ACR Convergence 2021
Whole Blood Hydroxychloroquine Levels Do Not Correlate with QTc Intervals in a Cohort of 84 SLE Patients: Evidence That Antimalarials Are Not Associated with Cardiac Conduction System Toxicity
Mayce Haj-Ali¹ and H. Michael Belmont², ¹NYU Grossman School of Medicine, New York, NY, ²NYU School of Medicine, New York, NY
Background/Purpose: Hydroxychloroquine (HCQ) is an antimalarial drug used in the treatment of systemic lupus erythematous (SLE). There is limited data assessing cardiac toxicity as arrhythmias…
Abstract Number: 1707 • ACR Convergence 2021
A Bioengineered Probiotic for the Oral Delivery of an Immunomodulator in Rheumatoid Arthritis
Yuqing Wang¹, Duolong Zhu¹, Laura Ortiz-Velez², Jacob Perry¹, Michael Pennington³, Joseph Hyser¹, Robert Britton¹ and Christine Beeton¹, ¹Baylor College of Medicine, Houston, TX, ²TMC Innovation, Houton, ³AmbioPharm Inc., North Augusta, SC
Background/Purpose: CCR7- effector memory T (TEM) lymphocytes are targets for immunomodulation for the treatment of rheumatoid arthritis (RA). Following activation, TEM cells upregulate the expression…
Abstract Number: 1649 • ACR Convergence 2021
Parameters by FDG-PET/CT Are Useful for Predicting Spontaneous Regression in MTX Associated Lymphoproliferative Disorder
Tomohiro Kameda¹, Shusaku Nakashima¹, Hiromi Shimada¹, Risa Wakiya¹, Mai Fahmy Mansour¹, Mikiya Kato¹, Koichi Sugihara¹, Rina Semba¹, Mao Mizusaki¹, Norimitsu Kadowaki¹ and Hiroaki Dobashi², ¹Kagawa University, Takamatsu, Japan, ²Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kita-gun, Japan
Background/Purpose: Methotrexate associated lymphoproliferative disorder (MTX-LPD) has various histological types from benign and malignant. Some MTX-LPDs spontaneously regress after discontinuation of MTX, even though they…
Abstract Number: 1522 • ACR Convergence 2021
Potential Predictors of Persistence in Immune Check Point Inhibitor Induced Arthritis
Anu Desai¹, Lakshmi Priya Shadananan¹, Adam Croft², Lalit Pallan¹, Neil Steven³ and Benjamin Fisher⁴, ¹University of Birmingham, Birmingham, United Kingdom, ²University of Birmingham, Halesowen, United Kingdom, ³Institute of Immunology and Immunotherapy/University of Birmingham, Birmingham, United Kingdom, ⁴Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham; National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre and Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
Background/Purpose: Immune Check Point Inhibitors (ICIs) are widely used in Oncology and are associated with multiple autoimmune and systemic inflammatory reactions called immune-related adverse events.…
Abstract Number: 0003 • ACR Convergence 2021
Clinically Identifiable Autoreactivity Is Common in Severe SARS-CoV-2 Infection
Richard Ramonell¹, Matthew Woodruff², Mark Rudolph³, F. Eun-Hyung Lee¹ and Iñaki Sanz⁴, ¹Emory University, Atlanta, GA, ²Emory University, Decatur, GA, ³Exagen Inc., Vista, CA, ⁴Emory University School of Medicine, Atlanta, GA
Background/Purpose: A massive expanson of plasmablasts or antibody secreting cells (ASC) have been shown in severe patients with SARS-CoV-2 infection and in patients with autoimmune…
Abstract Number: 0002 • ACR Convergence 2021
Salivary Sodium Levels in the Parotid Salivary Gland of SS Patients Suggest B-cell Mediated Epithelial Sodium Channel Disruption
Sarah Pringle¹, Bas Berkhof¹, Martha S. van Ginkel², Silvia Liefers¹, Bert van der vegt², Fred Spijkervet², Hendrika Bootsma¹, Arjan Vissink¹ and Frans Kroese¹, ¹University Medical Center Groningen, Groningen, Netherlands, ²University of Groningen, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Patients with Sjögren’s syndrome (SS) suffer from significantly reduced saliva production. Saliva is important for oral health. A careful of sodium, chloride, potassium and…
Abstract Number: 0004 • ACR Convergence 2021
Unappreciated Systemic Metabolic Functions of the Canonical B Cell Cytokines, BAFF and APRIL: Regulation of Lipolysis and Non-shivering Thermogenesis and Protection from Obesogenic Diet Induced Weight Gain
Isaac Harley¹, Calvin Chan², Paul Pfluger³, Trompette Aurelien⁴, Traci Stankiewicz⁵, Jessica Allen⁵, Maria Moreno-Fernandez⁵, Michelle Damen⁵, Jarren Oates⁵, Pablo Alarcon⁵, Jessica Doll⁶, Matthew Flick⁷, Leah Flick⁸, Juan Sanchez-Gurmaches⁹, Rajib Mukherjee⁹, Rebekah Karns¹⁰, Michael Helmrath¹¹, Thomas Inge¹², Stuart Weisberg¹³, Sunje Pamp¹⁴, David Relman¹⁵, Randy Seeley¹⁶, Matthias Tschoep¹⁷, Chris Karp¹⁸ and Senad Divanovic⁸, ¹University of Colorado Anschutz Medical Campus, Aurora, CO, ²University of Cincinnati, Cincinnati, OH, ³Technical University of Munich, Munich, Germany, ⁴Le Centre hospitalier universitaire vaudois, Lausanne, Switzerland, ⁵Cincinnati Children's Hospital Medical Center, Division of Immunobiology, Cincinnati, OH, ⁶Cincinnati Children's Hospital Medical Center, Division of Immunobiology, Cincinn, OH, ⁷Division of Experimental Hematology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁸Division of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁹Division of Endocrinology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ¹⁰Division of Gastroenterology, Hepatology and Nutrition, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ¹¹Pediatric General and Thoracic Surgery, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ¹²Department of Surgery, Children’s Hospital Colorado, Aurora, CO, ¹³Columbia University Medical Center, New York, NY, USA, New York, NY, ¹⁴Danmarks Tekniske Universitet, Lyngby, Denmark, ¹⁵Department: Medicine - Med/Infectious Diseases - Stanford University, Stanford, ¹⁶Department of Surgery, Internal Medicine and Nutritional Sciences, University of Michigan, Ann Arbor, MI, ¹⁷Division of Metabolic Diseases, Technische Universität München, Munich, Germany, ¹⁸Division of Molecular Immunology, Cincinnati Children’s Hospital Medical Center, Cincinnati
Background/Purpose: The impact of immune mediators on weight homeostasis and systemic metabolism remains underdefined. Interrogation of resistance to diet-induced obesity in mice lacking a negative…
Abstract Number: 0006 • ACR Convergence 2021
Metabolic Characteristics of Age-related B Cells in Lupus-prone Mice and Effects on Follicular Helper T Cells
Ivan Ramirez¹, Betty Diamond² and Sun Jung Kim³, ¹Northwell, Little Neck, NY, ²Northwell Health, Manhasset, NY, ³Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: Since the description of age-associated B cells (ABC), there has been a growing interest in the role of these cells in autoimmunity. Evidence suggests…
Abstract Number: 0005 • ACR Convergence 2021
Maturation and Dysfunction of Autoreactive B Cell Clones in Tissues of Patients with Sjögren’s Syndrome
Mathijs Broeren¹, Giulia Balzaretti², Jing Wang³, Patricia Groenen¹, Barbera van Schaik⁴, Tim Chataway³, Charlotte Kaffa¹, Sander Bervoets¹, Konnie Hebeda¹, Gergana Bounova⁵, Ger Pruijn¹, Tom Gordon³, Niek De Vries⁶ and Rogier Thurlings⁷, ¹Radboud University Medical Center, Nijmegen, Netherlands, ²Amsterdam, Netherlands, ³Flinders University, Adelaide, Australia, ⁴Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁵Enpicom BV, Den Bosch, Netherlands, ⁶Amsterdam UMC, Amsterdam, Netherlands, ⁷Radboud University Medical Centre, Nijmegen, Netherlands
Background/Purpose: Sjögren's syndrome (SjS) involves chronic inflammation of exocrine glands that can be complicated by extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT). We…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].